abstract |
A monoclonal antibody against a programmed cell death factor 1 ligand (PDL-I) or antigen combining segment is provided. Monoclonal antibodies can specifically bind to PDL-1 to release inhibition of PDL-1 in body immunity, thereby activating T lymphocytes. Also provided are pharmaceutical compositions comprising the monoclonal antibodies described above and uses thereof. |